Why do healthcare companies expand their target market too quickly?
Healthcare companies often expand their target market too quickly.
One successful customer in cardiology becomes a cardiology strategy. An inbound lead from an ACO becomes an ACO strategy. A large health system expresses interest and suddenly enterprise is part of the plan.
The result is commercial fragmentation.
A new opportunity can be valuable evidence. A buying signal can tell you that a market deserves further investigation. But neither, by itself, is enough evidence to pivot a GTM strategy.
How should healthcare markets be compared before scaling sales?
Instead of asking whether a market could buy, evaluate competing markets against consistent criteria.
Consider problem severity, number of qualified organizations, reimbursement and economic alignment, buyer accessibility, sales-cycle length, competitive saturation, implementation complexity, existing customer evidence, contract value, and observable buying signals.
This creates an evidence-based way to allocate scarce commercial resources.
What is the difference between a buying signal and a market strategy?
A buying signal should influence account priority. A pattern of buying signals, customer evidence and market behavior can influence market strategy.
Those should not be confused.
If three cardiology groups begin hiring RPM staff, that may justify moving those organizations higher in the pipeline. It does not necessarily mean the company should suddenly reposition its commercial strategy around cardiology.
Market decisions require more evidence.
Why is delivery fit as important as commercial fit?
A market is only attractive if you can successfully serve it.
There is another question healthcare companies often overlook: If we win this customer, are we actually prepared to deliver?
Revenue opportunity can make companies stretch their definition of an ideal customer. But an organization can be commercially attractive and still be operationally wrong for the business.
A company may lack experience in the specialty. Its software may not support the necessary workflow or EHR environment. Implementation resources may be insufficient. Clinical or operational staffing may not be able to support the population. Customer success may not understand the buyer's operating model. The economics may also change significantly at a different customer size.
These are not problems to solve after the contract is signed. They are part of market selection.
Why can winning the wrong customer cost more than losing the deal?
There is understandable pressure—particularly in an early-stage company—to take revenue when it is available.
But winning a customer you cannot effectively serve can create consequences well beyond a difficult implementation.
A poor-fit customer can consume disproportionate leadership and operational resources. Product teams begin building one-off functionality. Customer-success teams spend their time solving exceptions. Margins deteriorate. The customer becomes dissatisfied. Renewals become difficult.
In healthcare, the consequences can be even greater because reputation travels through relatively concentrated professional networks. The customer you stretched to win may become the customer unwilling to provide a reference.
That matters.
What two questions define a true target market?
Before prioritizing a market, leadership should effectively answer two sets of questions.
- Can we win here? Is there a meaningful problem? Can we identify the buyer? Is there sufficient economic value? Are there buying signals? Do we have customer evidence? Can we compete effectively?
- Can we succeed here after we win? Can our product support the workflows? Do we understand the specialty? Can we implement successfully? Do we have the necessary operational or clinical infrastructure? Can we support the customer without excessive customization? Can we produce an outcome worth referencing?
Why does concentration accelerate learning for early-stage healthcare companies?
A company with a five-person commercial team cannot effectively pursue independent practices, large health systems, ACOs, FQHCs and national MSOs simultaneously.
Each has different buyers, economics, procurement processes, workflows, implementation requirements and messaging.
Concentration accelerates learning.
When similar organizations receive similar messaging around similar problems, patterns become visible much faster. Product and operational teams also become better at serving a more consistent customer profile.
That creates something more valuable than a few isolated wins: repeatability.
How should buying signals refine strategy without rewriting it?
Buying signals are extremely valuable because markets are not static.
A new executive, acquisition, new practice opening, technology change, value-based contract, staffing increase or new clinical program can dramatically increase the priority of an individual account.
But there is a hierarchy to the intelligence.
- One signal changes an account's priority.
- Repeated signals across similar organizations reveal a pattern.
- Patterns combined with customer outcomes can justify changing market strategy.
When has a healthcare company earned the right to expand into a new market?
A healthcare company should know why its first market works before moving aggressively into the second.
That means understanding the customer profile, buyer, trigger, value proposition, sales cycle, implementation requirements, common objections and—critically—the company's ability to deliver successfully after the contract is signed.
Then expansion becomes intentional.
The question is no longer: “Could we sell to this market?” It becomes: “Do we have evidence that we can repeatedly identify, win, serve and retain customers in this market?”
That is a much higher standard. And it is the difference between pursuing revenue and building a scalable healthcare business.